 Delcath Systems Announces A New Site For The Phase III Doxorubicin Clinical Trial In San Antonio, TX - 19-8-2006 12:14:56
Delcath Systems,Inc. (Nasdaq: DCTH) ("Company") announced today that the Methodist HealthCare System ("Site") has joined Delcath's Phase III clinical trial for thetreatment of metastatic melanoma that has spread to the liver, using theDelcath system with Doxorubicin, an approved anti-cancer agent. The Site, located in San Antonio, TX, has named Dr. Rohit Kapoor, M.D. [click link for full article] more »
|